

Table of Contents

| | |
|--|----|
| Highlights | 2 |
| To Our Stakeholders | 4 |
| Summary of Accomplishments in Fiscal 2006/ Management Tasks for Fiscal 2007 | |
| Corporate Philosophy/Relationship with Our Stakeholders | 10 |
| Corporate Governance | 11 |
| Compliance | 12 |
| Risk Management | 13 |
| Intellectual Property | 14 |

Corporate Activities and Performance of Fiscal 2006

Contribution to Society through

Pharmaceutical Business

| | |
|--|----|
| Industry Trends | 17 |
| The Special Feature in the U.S. Business Operation | 18 |
| Research and Development | 22 |
| Pipeline | 24 |
| Production System | 27 |
| International Strategic Products (Ethical Drugs)/ Consumer Healthcare Drugs & Quasi-Drugs (Consumer Healthcare Business) | 28 |
| Marketing | |
| Japan | 30 |
| U.S.A. | 32 |
| Europe | 33 |
| Developing Superior Medicines Corresponding to Stakeholders' Aspirations | 34 |

Relationship with Our Stakeholders

| | |
|---|----|
| Relationship with Society - Japan, U.S.A., Europe and Asia | 37 |
| History of Takeda | 41 |
| Relationship with Environment | |
| Basic Principles on the Environment / Environment and Safety Management Structure | 42 |
| Policies and Achievements | 43 |
| Business Activities and Environmental Impacts | 44 |
| Energy Conservation/Prevention of Global Warming | 46 |
| Waste Reduction/Reduction in Emissions of Chemical Substances/Air and Water Quality Conservation | 48 |
| Environmental Impacts associated with Business Activities | 50 |
| Accident Prevention/Environmental Accounting | 51 |
| Relationship with Suppliers | 52 |
| Relationship with Employees | 54 |
| Global Meeting | 58 |
| Our responsibilities and enthusiasm dealing with the new drug: <i>Rozerem</i> | |
| Financial Section | 60 |
| Independent Auditors' Report | 86 |
| Board of Directors, Auditors and Corporate Officers | 87 |
| Main Subsidiaries and Affiliates | 88 |
| Corporate Information | 90 |

Editorial Policy

Aiming to facilitate understanding of Takeda's activities in a comprehensive manner, through the provision of both financial and non-financial information, including CSR (corporate social responsibility) activities, we have issued an integrated version of the Annual and CSR Report since fiscal 2006. When preparing this integrated report, we have prioritized the inclusion of items which should be conveyed to stakeholders, concerning key aspects of our financial and social responsibilities. We sincerely hope that our stakeholders understand Takeda's corporate activities; centering on both these areas.

This report covers a total of 68 Takeda group companies, consisting of Takeda Pharmaceutical Company Limited, and its 46 consolidated subsidiaries and 21 equity method affiliates. As for the disclosure of non-financial information, it is referred to the "Sustainability Reporting Guidelines"^{*1} issued by the Global Reporting Initiative (GRI) and AA 1000^{*2}.

*1 Sustainability Reporting Guidelines:

Guidelines that specify the framework of the sustainability report issued by the Global Reporting Initiative and applicable worldwide.

*2 AA 1000:

Guidelines that specify the systematic process in which stakeholders are involved in the course of developing a communication system, etc. issued by a British firm, AccountAbility.

Regarding the Front Cover

The Japanese calligraphy: 挑 (challenge) shown on the front cover symbolizes Takeda's spirit of challenge, continuing to challenge toward the development of superior pharmaceutical products as a "World-Class Pharmaceutical Company with Japanese Origin." The calligraphy piece was composed by a Japanese calligrapher, Mr. Souun Takeda, followed by FY2006.

Precautions Regarding Forward-Looking Statements

This annual report includes forward-looking statements regarding Takeda's plans, prospects, strategies and accomplishments, etc. These prospects are the result of assessment obtained from information currently available, and since the actual performance could be influenced by various risks and uncertainty, it shall be noted that the course of action could differ substantially from those prospects. Factors that could affect future prospects would include, but are not limited to, economic circumstances surrounding Takeda's domain identity, competitive pressures, relevant laws and regulations, change in the status of product development, exchange rate risk and so on.

*The contents of this annual report are written based on the information as of FY 2006 (April 1, 2006 to March 31, 2007) with some activities in FY 2007 being included.